GlaxoSmithKline PLC

LON100:GSK, Oct 24, 07:59 UTC FTSE 100 real-time data - Disclaimer Currency in GBP

Latest LON100:GSK News

Filter your feed

Settings

Authority
General News Provider Financial News Provider
Relevance
More Stories Less News
Focus (count of companies in a story)
Very Focused Everything

Save Changes

Want more control? Try Elite for free

You can sign up for an elite account now and get news filtering + many more benefits including:

  1. Greater Coverage
  2. More Control
  3. Access to our Opportunity Index
Become Elite I'm not interested
News

Britain backs GSK's gene therapy for 'bubble boy' syndrome

GSK

(Reuters) - GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000). Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. "Costing 594,000 euros, the treatment is usually given once only and the effects are thought to be life-long," it added. The draft guidance marks the first time NICE has applied its new cost effectiveness limits for treatments for very rare conditions.

Read Full Details

Story Sources

businessinsider.com
Topics:
  • Business
  • Health
  • Technology
News

UPDATE 1-GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

GSK

"Although largely expected, today’s approval is an important one for GSK -- a new product with a clear best-in-class profile," Berenberg analysts said on Monday. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe. The FDA approved Shingrix, which is given in two doses, for adults aged 50 and over. Shingrix is more effective than Zostavax, the only currently available shingles prevention vaccine, which is given as a single dose.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

GSK

"Although largely expected, today’s approval is an important one for GSK -- a new product with a clear best-in-class profile," Berenberg analysts said on Monday. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe. The FDA approved Shingrix, which is given in two doses, for adults aged 50 and over. Shingrix is more effective than Zostavax, the only currently available shingles prevention vaccine, which is given as a single dose.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

A Look at the Health of GlaxoSmithKline plc (LSE:GSK)’s Shares

GSK

Here we will take a look into some valuation metrics for GlaxoSmithKline plc LSE:GSK shares. GlaxoSmithKline plc (LSE:GSK) presently has a 10 month price index of 1.03904. The price index is calculated by dividing the current share price by the share price ten months ago. The Price to Cash Flow for GlaxoSmithKline plc (LSE:GSK) is 10.793192. This ratio is calculated by dividing the market value of a company by cash from operating activities. The Price to book ratio is the current share price of a company divided by the book value per share.

Read Full Details

Story Sources

akronregister.com
Topics:
  • Business
  • Financial
News

Short-Term Trade Secrets: GlaxoSmithKline plc (NYSE: GSK) – Alpha Beta Stock

GSK NDAQ

When stocks are *very* In Play one can see a RVOL of 5 and above. In Play Stocks are volatile enough to produce good risk and reward trading opportunities for both bull and bear traders intraday. He has formerly spent over 5 years as a trader in U.S. Stock Market and is now semi-stepped down. Often, a boost in the volume of a stock is a harbinger of a price jump, either up or down.

Read Full Details

Story Sources

alphabetastock.com
Topics:
  • Business
  • Financial
News

GSK Vaccines set to bring Shingrix, the latest shingles vaccination innovation, to market - Drug Store News

GSK

LONDON — GlaxoSmithKline on Friday announced that the Food and Drug Administration has approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. On Oct. 13, Shingrix was approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Read more in this special report. Special Report: Congress signs OTC hearing aid bill.

Read Full Details

Story Sources

drugstorenews.com
Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Brainstorm Health: Robot Surgeons, GSK Shingles Vaccine, Uninsurance Rate

GSK

These products are designed to help make a process (stroke rehab, seizure monitoring, breast milk pumping) easier for consumers and patients, not the myriad other players in the health system (physicians, hospitals, insurers). “When a woman undergoes breast reconstruction, surgeons stretch the existing tissue by injecting saline into implanted bladders—a painful process that demands doctor visits, needles, and analgesics. One more great story to highlight: Today, Fortune published online a fascinating read about Intuitive Surgical, a robotic surgery pioneer that, as we said, is turning “medical sci-fi into reality. As Cliff so kindly mentioned above, I had an opportunity to explore the corporate DNA—and impressive, pioneering technology—at the heart of Intuitive Surgical, the company that’s long been dominating the robotic-assisted surgery space.

Read Full Details

Story Sources

fortune.com
Topics:
  • Business
  • Health
  • Financial
  • Science
News

Vaccine approval buoys GSK new drug push

GSK

The regulatory OK will put GSK in direct competition with Merck & Co, which currently markets the only approved vaccine for the painful rash caused by the varicella zoster virus. GlaxoSmithKline plc on Friday secured a key approval from the Food and Drug Administration for its shingles vaccine Shingrix, boosting the growth potential for the British drugmaker's vaccines business as the company turns to new drugs to recharge revenues. GSK, however, estimates that Zostavax only reaches about 30% of the potential patient population and believes Shingrix's superior efficacy could make it a more meaningful treatment for a wide group of patients. Success with Shingrix opens up a potentially billion-dollar market for GSK.

Read Full Details

Story Sources

biopharmadive.com
Topics:
  • Business
  • Health
News

GSK picks up NICE recommendation for Strimvelis, a €594,000 gene therapy

GSK

NICE reviewers recommended the therapy for patients when no suitable stem cell donor is available. For treatment with Strimvelis, teams collect patients' bone marrow cells, then modify and reinject them. When GSK announced that decision, just two patients had received treatment with Strimvelis, and another two were slated for treatment. ” GSK isn't leaving "cell and gene therapy R&D, but will focus on oncology and more common indications," she added.

Read Full Details

Topics:
  • Health
  • Technology
News

How to partner with the private sector: Lessons from CARE International

GSK BARC

Live Well recruits and trains community health entrepreneurs, who sell health care products as part of a basket of goods in rural and semi-rural regions. As a result, GSK sold more than 55,000 health care products, of which about half are its own brand. It is providing health care products that people in communities simply could not get before. For full access to the content of the article sign in or join Devex.

Read Full Details

Story Sources

devex.com
Topics:
  • Business
  • Health
  • Financial
News

NICE Approves GSK’s Gene Therapy Strimvelis

GSK

The Strimvelis gene therapy will be offered at a price of $700,000 for a life-long treatment. The healthcare cost watchdog in Britain, NICE – National Institute for Health and Care Excellence, has given approval for a gene therapy developed by GlaxoSmithKline plc (ADR)(NYSE:GSK) for the treatment of adenosine deaminase deficiency, Strimvelis. The approval of Strimvelis by the National Institute for Health and Care Excellence comes at a time when GlaxoSmithKline’s shingles vaccine for adults who are aged 50 and over, Shingrix, has been approved by the U.S. Food and Drug Administration. Prior to the Food and Drug Administration granting the approval, a phase 2 clinical trial had been conducted on participants numbering over 38,000. The trial results demonstrated that the vaccine was effective against Shingles 90% of the time in all ages.

Read Full Details

Story Sources

marketexclusive.com
Topics:
  • Health
  • Technology
  • Financial
News

Thrashing Stocks: Dextera Surgical Inc. (NASDAQ:DXTR), GlaxoSmithKline plc (NYSE:GSK), Xunlei Limited (NASDAQ:XNET), Marathon Petroleum Corporation (NYSE:MPC) – The Street Point

GSK

The GSK’ Stock performances for weekly, Monthly, Quarterly, half-yearly & year-to-date are mentioned below:-. The quarterly performance for the stock is -3.31%, while the half-yearly performance is -0.68%. The company has experienced volume of 2,754,524 shares while on average the company has a capacity of trading 259.28K share. During the last trade, stock’s minimum price has been reached out at $5.3 while the maximum trading price moved at $6.75. Currently the stock price is moving 14.83% off from the highest level of twelve months and 111.58% above from twelve months low.

Read Full Details

Story Sources

thestreetpoint.com
Topics:
  • Business
  • Financial
News

GSK’s ‘bubble baby’ gene therapy passes NICE’s new stricter test - Pharmaphorum

GSK

The one-off therapy costs €594,000, equivalent to £505,000 or $697,750, but despite this very high price, NICE judged the drug to be cost effective, as it helps more children survive the disease than the current standard stem cell transplant treatment. The decision is also significant because Strimvelis is the first drug to be appraised using NICE’s new cost effectiveness limits for treatments for very rare conditions, £100,000 per QALY gained, which it just to be significantly under compared to stem cell treatment. One of the biggest limiting factors for Strimvelis is its manufacturing: the only approved production centre is in Milan, and patients have to travel to Italy to receive the treatment. This is because the therapy has a 6-hour shelf life, requiring patients to visit the Hospital San Raffaele Telethon Institute for Gene Therapy in Milan for treatment.

Read Full Details

Story Sources

pharmaphorum.com
Topics:
  • Business
  • Health
  • Technology
  • Financial
News

FDA approves better vaccine against painful shingles virus

GSK MRK

U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus. It will be the second shingles vaccine in the U.S. market. Meanwhile, Merck has been testing a different vaccine on cancer patients and people with compromised immune systems. Chickenpox was a very common childhood illness until a Merck vaccine was introduced two decades ago;

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Form 6-K GLAXOSMITHKLINE PLC For: Oct 23

GSK

On 13 October 2017, Shingrix was approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Shingrix approved in the US for prevention of shingles in adults aged 50 and over. N Engl J Med. N Eng J Med.

Read Full Details

Story Sources

streetinsider.com
Topics:
  • Business
  • Health
  • Technology
  • Financial